We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Prismic Pharmaceuticals Acquires Scarista's Exclusive License to Amarin's Omega-3 Patents
News

Prismic Pharmaceuticals Acquires Scarista's Exclusive License to Amarin's Omega-3 Patents

Prismic Pharmaceuticals Acquires Scarista's Exclusive License to Amarin's Omega-3 Patents
News

Prismic Pharmaceuticals Acquires Scarista's Exclusive License to Amarin's Omega-3 Patents

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Prismic Pharmaceuticals Acquires Scarista's Exclusive License to Amarin's Omega-3 Patents"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Commenting on this acquisition, Peter Moriarty, the Chairman and co-founder of the company, stated, "This is an important milestone in the development of Prismic Pharmaceuticals. Having gained access to the robust patents through the acquisition of Scarista, Prismic is planning to partner with one or more pharmaceutical companies in order to maximize the considerable commercial opportunity the patents offer in the CNS area."

"There is already an established body of research and clinical experience indicating the therapeutic benefits and safety of highly purified forms of EPA and DHA for the treatment of cardiovascular disease. There is also similar data relating to their use in the treatment of a number of CNS disorders," Moriarty added. "Prismic, therefore, believes that any company licensing our IP will have the opportunity to bring patent-protected formulations to market relatively expeditiously."

Advertisement